01:58 AM EST, 11/05/2026 (MT Newswires) -- ANI Pharmaceuticals launched a cash takeover offer for Egetis Therapeutics (EGTX.ST), valuing the Swedish pharmaceutical company at 5.30 billion kronor. The US-based specialty pharmaceutical company offered 11.25 kronor per Egetis share, and 65.8 million kronor for the convertible loan 2023:1 and 6.99 kronor per warrant 2023/2033:1 issued by Egetis, according to separate Thursday filings. Egetis' board unanimously recommended the offer to shareholders and holders of the convertible loan and warrants. The bidder secured commitments in favor of the offer from 42.2% of Egetis shareholders. The acceptance period will run from Nov. 20 through Dec. 18. The offer is subject to a 90% acceptance threshold and regulatory clearances, among other conditions. Upon completion, ANI plans to delist Egetis' shares from Nasdaq Stockholm.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.